These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

106 related articles for article (PubMed ID: 16280051)

  • 1. Clinical trial update: International Breast Cancer Study Group.
    Price KN; Goldhirsch A;
    Breast Cancer Res; 2005; 7(6):252-4. PubMed ID: 16280051
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical trial update: National Cancer Institute of Canada.
    Pritchard K; Whelan T
    Breast Cancer Res; 2005; 7(2):48-51. PubMed ID: 15743510
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The impact of the physician on the accrual to randomized clinical trials in patients with primary operable breast cancer.
    Kaas R; Hart AA; Rutgers EJ
    Breast; 2005 Aug; 14(4):310-6. PubMed ID: 16085238
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Quality of life assessment in International Breast Cancer Study Group (IBCSG) trials: practical issues and factors associated with missing data.
    Bernhard J; Peterson HF; Coates AS; Gusset H; Isley M; Hinkle R; Gelber RD; Castiglione-Gertsch M; Hürny C
    Stat Med; 1998 Mar 15-Apr 15; 17(5-7):587-601. PubMed ID: 9549808
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The best available adjuvant treatments are within the framework of clinical trials. The International Breast Cancer Study Group.
    Goldhirsch A; Gelber RD; Castiglione M; Price KN; Rudenstam CM; Lindtner J; Collins J; Senn HJ; Cavalli F; Galligioni E
    Isr J Med Sci; 1995; 31(2-3):144-54. PubMed ID: 7744584
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Quality of life assessment in patients receiving adjuvant therapy for breast cancer: the IBCSG approach. The International Breast Cancer Study Group.
    Bernhard J; Hürny C; Coates AS; Peterson HF; Castiglione-Gertsch M; Gelber RD; Goldhirsch A; Senn HJ; Rudenstam CM
    Ann Oncol; 1997 Sep; 8(9):825-35. PubMed ID: 9358933
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The role of aromatase inhibitors as adjuvant therapy for early breast cancer in postmenopausal women.
    Mouridsen HT; Robert NJ
    Eur J Cancer; 2005 Aug; 41(12):1678-89. PubMed ID: 16098456
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Personalized adjuvant therapies: lessons from the past: the opening address by the St. Gallen 2013 award recipient.
    Goldhirsch A
    Breast; 2013 Aug; 22 Suppl 2():S3-7. PubMed ID: 24074788
    [TBL] [Abstract][Full Text] [Related]  

  • 9. BCIRG 001 molecular analysis: prognostic factors in node-positive breast cancer patients receiving adjuvant chemotherapy.
    Dumontet C; Krajewska M; Treilleux I; Mackey JR; Martin M; Rupin M; Lafanechère L; Reed JC
    Clin Cancer Res; 2010 Aug; 16(15):3988-97. PubMed ID: 20576719
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Refining the postmenopausal breast cancer treatment paradigm: the FACE trial.
    Monnier A
    Expert Rev Anticancer Ther; 2006 Oct; 6(10):1355-9. PubMed ID: 17069521
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Herceptin in early breast cancer: a call for judicious use.
    Thorat MA
    Natl Med J India; 2005; 18(6):315-7. PubMed ID: 16483033
    [No Abstract]   [Full Text] [Related]  

  • 12. Speed of Accrual Into Phase III Oncology Trials: A Comparison Across Geographic Locations.
    Ruther NR; Mathiason MA; Wee SK; Emmel AE; Go RS
    Am J Clin Oncol; 2015 Dec; 38(6):575-82. PubMed ID: 24517955
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Are all aromatase inhibitors the same? A review of controlled clinical trials in breast cancer.
    Berry J
    Clin Ther; 2005 Nov; 27(11):1671-84. PubMed ID: 16368441
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Quality of life assessment in the International Breast Cancer Study Group: past, present, and future.
    Hürny C; Bernhard J; Coates A
    Recent Results Cancer Res; 1998; 152():390-5. PubMed ID: 9928574
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A 38-gene expression signature to predict metastasis risk in node-positive breast cancer after systemic adjuvant chemotherapy: a genomic substudy of PACS01 clinical trial.
    Jézéquel P; Campone M; Roché H; Gouraud W; Charbonnel C; Ricolleau G; Magrangeas F; Minvielle S; Genève J; Martin AL; Bataille R; Campion L
    Breast Cancer Res Treat; 2009 Aug; 116(3):509-20. PubMed ID: 19020972
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Adjuvant zoledronic acid in patients with early breast cancer: final efficacy analysis of the AZURE (BIG 01/04) randomised open-label phase 3 trial.
    Coleman R; Cameron D; Dodwell D; Bell R; Wilson C; Rathbone E; Keane M; Gil M; Burkinshaw R; Grieve R; Barrett-Lee P; Ritchie D; Liversedge V; Hinsley S; Marshall H;
    Lancet Oncol; 2014 Aug; 15(9):997-1006. PubMed ID: 25035292
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The future of surgical research: the role of the American College of Surgeons Oncology Group.
    Posther KE; Wells SA
    Eur J Surg Oncol; 2005 Aug; 31(6):695-701. PubMed ID: 16023948
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The Breast International Group 1-98 trial: big results for women with hormone-sensitive early breast cancer.
    Monnier AM
    Expert Rev Anticancer Ther; 2007 May; 7(5):627-34. PubMed ID: 17492927
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Update of the Phase III trial 'GRETA' of surgery and tamoxifen versus tamoxifen alone for early breast cancer in elderly women.
    Mustacchi G; Scanni A; Capasso I; Farris A; Pluchinotta A; Isola G
    Future Oncol; 2015; 11(6):933-41. PubMed ID: 25383659
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Conservative local treatment versus mastectomy after induction chemotherapy in locally advanced breast cancer: a randomised phase III study (EORTC 10974/22002, LAMANOMA)--why did this study fail?
    Sinacki M; Jassem J; van Tienhoven G
    Eur J Cancer; 2005 Dec; 41(18):2787-8. PubMed ID: 16274985
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.